A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab

There is limited real-world evidence regarding patients with intermediate/poor-risk advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (NIVO+IPI) in England. This study aimed to describe characteristics, treatment patterns, and efficacy outcomes in these patients. A retrospective chart review of medical records in patients with aRCC receiving NIVO+IPI at any line of therapy between 5 April 2019 and 1 April 2022 in five sites across England was conducted. Data were analyzed descriptively overall, in patients with and without NIVO maintenance after NIVO+IPI initiation, and by prior nephrectomy status. In total, 128 patients (mean age 60.7 years [standard deviation 10.1], 71.1% male) were eligible; most received first-line (1L) NIVO+IPI (n = 122, 95.3%). Median follow-up was 13.6 months (interquartile range [IQR] 7.1–25.0). Median progression-free survival and overall survival (OS) were 7.6 months (95% confidence interval [CI]: 5.6, 13.1) and 30.7 months (95% CI: 22.5, not reached), respectively. Median OS was not reached in patients who received NIVO+IPI plus NIVO maintenance and patients with prior nephrectomy. Patients who received NIVO+IPI with NIVO maintenance and patients who had undergone prior nephrectomy experienced the most favorable survival outcomes, aligning with results from previous studies.

英国范围内，针对中危/不良风险晚期肾细胞癌（advanced renal cell carcinoma, aRCC）患者接受纳武利尤单抗（nivolumab）联合伊匹木单抗（ipilimumab，缩写NIVO+IPI）治疗的真实世界证据较为有限。本研究旨在描述该类患者的临床特征、治疗模式与疗效结局。本研究对2019年4月5日至2022年4月1日期间，英国5家医疗中心内所有接受NIVO+IPI治疗（任意治疗线数）的aRCC患者的病历开展回顾性图表审查。研究分别从整体人群、NIVO+IPI启动后接受或未接受纳武利尤单抗维持治疗的亚组，以及既往是否接受肾切除术的亚组进行描述性数据分析。最终共纳入128例符合入组标准的患者，平均年龄60.7岁（标准差10.1），男性占比71.1%；其中绝大多数接受一线（1L）NIVO+IPI治疗（n=122，占比95.3%）。中位随访时间为13.6个月（四分位距interquartile range, IQR：7.1~25.0个月）。中位无进展生存期（progression-free survival, PFS）为7.6个月（95%置信区间confidence interval, CI：5.6~13.1），中位总生存期（overall survival, OS）为30.7个月（95%CI：22.5，未达到）。接受NIVO+IPI联合纳武利尤单抗维持治疗的患者，以及既往接受肾切除术的患者，其中位OS均未达到。该两类患者均获得了最优的生存结局，与既往研究结果一致。